Levothyroxine magnesium
Pro Research Analysisby 
Searched over 200M research papers for "levothyroxine magnesium"
Levothyroxine and Magnesium: Interactions and Stability
Introduction to Levothyroxine and Magnesium
Levothyroxine is a synthetic form of the thyroid hormone thyroxine, used primarily to treat hypothyroidism. Magnesium, an essential mineral, plays a crucial role in numerous physiological processes, including enzyme function and muscle contraction. This article explores the interactions between levothyroxine and magnesium, focusing on their combined effects on inflammation and the stability of levothyroxine formulations.
Anti-Inflammatory Effects of Levothyroxine and Magnesium
Hypothyroidism and Inflammation
Hypothyroidism is associated with chronic low-grade inflammation, which increases the risk of cardiovascular diseases. In a study involving hypothyroid rats, it was found that hypothyroidism significantly elevated levels of inflammatory markers such as C-reactive protein (CRP), interleukin-6, tumor necrosis factor-α (TNF-α), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) .
Combined Therapy with Levothyroxine and Magnesium Sulfate
Treatment with either levothyroxine or magnesium sulfate (MgSO4) alone significantly reduced these inflammatory markers. However, the combination of levothyroxine and MgSO4 was more effective in decreasing CRP, interleukin-6, TNF-α, ICAM-1, and VCAM-1 levels compared to either treatment alone. This suggests that combined therapy may better alleviate chronic inflammation and reduce cardiovascular risk in hypothyroid patients .
Stability of Levothyroxine Formulations
Challenges with Tablet Stability
Levothyroxine tablets have faced numerous recalls due to degradation and failure to meet potency standards. The stability of levothyroxine sodium pentahydrate in tablets is influenced by the excipients used in the formulation. Studies have shown that tablets containing lactose anhydrous, starch, or microcrystalline cellulose failed to meet USP assay requirements after three months at 40°C/75% RH .
Role of Excipients and pH Modifiers
The stability of levothyroxine can be improved by using basic pH modifiers. Tablets formulated with dibasic calcium phosphate and basic pH modifiers such as sodium carbonate, sodium bicarbonate, or magnesium oxide met USP assay requirements at both three and six months . Additionally, magnesium stearate and sodium stearyl fumarate did not negatively affect the stability of levothyroxine, highlighting the importance of selecting appropriate excipients to maintain drug potency .
Liquid Levothyroxine Formulations
Overcoming Absorption Interference
New levothyroxine formulations, particularly liquid forms, have been developed to overcome absorption issues caused by interfering drugs such as proton pump inhibitors, calcium or iron supplements, and aluminum/magnesium hydroxide. These liquid formulations can be taken simultaneously with these interfering drugs, providing a more flexible and reliable treatment option for patients .
Conclusion
The combination of levothyroxine and magnesium sulfate offers significant benefits in reducing inflammation and cardiovascular risk in hypothyroid patients. Additionally, the stability of levothyroxine formulations can be enhanced by using appropriate excipients and pH modifiers, with liquid formulations providing a solution to absorption interference. These insights underscore the importance of considering both therapeutic efficacy and formulation stability in the management of hypothyroidism.
Sources and full results
Most relevant research papers on this topic